A股黄金、有色金属板块因此掀起涨停潮，白银有色（维权）七连板，中国黄金四连板，四川黄金、湖南黄金等纷纷涨停。 每经记者｜王砚丹 每经编辑｜彭水萍 1月28日，A股三大指数涨跌不一，截至收盘，沪指涨0.27%，收报4151.24点；深证成指涨0.09%，收报14342.89点；创业板指跌0.57%，收报3323.56点。 沪深京三市成交额达到29926亿元，较昨日放量709亿元。 个股方面，上涨股票数量超过1700只，逾80只股票涨停。贵金属、珠宝首饰、采掘行业、有色金属、小金属、煤炭行业涨幅居前，光伏设备、医疗器械、 医疗服务、生物制品、航天航空板块跌幅居前。 今日收盘后，2026年A股1月行情仅剩两个交易日。最近半个月以来，对很多投资者来说，其实赚钱并没有那么容易。 沪指虽然一直在4100点左右横盘，但个股分化明显。就像今日盘中，A股整体还是延续涨少跌多态势，超60%个股飘绿。如果没有踩中热点，投资体验并 不好。 这种情况和去年8月有些相似。当时轮动的是寒武纪、宁德时代等高价股。而从最近的盘面来看，热点一直围绕有色、存储等板块。它们上涨的核心逻辑 都绕不开"产品涨价"这一关键词，这也让两大板块成为1月A股市 ...

风险提示：本文所提到的观点仅代表个人的意见，所涉及标的不作推荐，据此买卖，风险自负。 作者： 陈达美股投资 来源：雪球 第一个将IPO比喻成抽血的人值一个诺贝尔经济文学奖，因为事实就是如此，如果一个市场的IPO抽血太狠，这个市场就是会倾向于不长个。 整个2025年港股市场IPO，117个新股上市，一共募资2867亿港币，折合368亿美元，创四年新高。许多文章与报道说2025年的港股全球IPO第一， 这是直接粘贴复制AI、不做事实核查的fake news，因为美股2025年全年IPO募资是在700亿美元以上；如果港股IPO是大盘鸡的话，那美股就是大 盘鹅。 但考虑到港股总体量大概6.4万亿美元，而美股是近70万亿，你做一下除法，新股募资/总市值，可得美股为10个bps，而港股高达57.5个。如果这可 以看成某个市场IPO的强度值的话，那这方面阿港显然冠绝环宇。 这就好比，你只有7只鹅，而隔壁老王家有70只；结果拔了一年鹅毛，一算，你拔下来的鹅毛至少是老王家的一半，等于以一敌五，此时求你家大 鹅的心理阴影面积。如果故意拔鹅罪能判刑，那你至少是个无期。也难怪2025年最后两个月，你家鹅被拔得陷入了重度抑郁之中，行情 ...

1月28日，A股三大指数涨跌不一，截至收盘，沪指涨0.27%，收报4151.24点；深证成指涨0.09%，收报14342.89点；创业板指跌0.57%，收报3323.56点。 沪深京三市成交额达到29926亿元，较昨日放量709亿元。 个股方面，上涨股票数量超过1700只，逾80只股票涨停。贵金属、珠宝首饰、采掘行业、有色金属、小金属、煤炭行业涨幅居前，光伏设备、医疗器械、 医疗服务、生物制品、航天航空板块跌幅居前。 今日收盘后，2026年A股1月行情仅剩两个交易日。最近半个月以来，对很多投资者来说，其实赚钱并没有那么容易。 沪指虽然一直在4100点左右横盘，但个股分化明显。就像今日盘中，A股整体还是延续涨少跌多态势，超60%个股飘绿。如果没有踩中热点，投资体验并 不好。 有色方面以黄金为代表。1月国际金价也涨势惊人，今日现货黄金盘中一度突破5200美元，再创历史新高。2025年最后一个交易日，现货黄金报收4310.89 美元，也就是说，2026年开年不到一个月时间，现货黄金已大涨超过900美元。 A股黄金、有色金属板块因此掀起涨停潮，白银有色七连板，中国黄金四连板，四川黄金、湖南黄金等纷纷涨停。 另外，国际 ...

1月28日，沪指、深成指冲高回落，创业板指高开低走，盘中一度跌超1%。截至收盘，沪指涨0.27%，深成指涨0.09%，创业板指跌0.57%。沪深两市成交 额2.99万亿，较上一个交易日放量708亿。盘面上，全市场超3600只个股下跌。 资源股全天领涨，贵金属、油气、电解铝方向轮番爆发。黄金、有色金属板块午后持续拉升，云铝股份（000807）、华峰铝业（601702）、中金黄金 （600489）、北方铜业（000737）、赤峰黄金（600988）等20余股涨停。 | 白银有色 | 13.81 | 10.04% | 0.00% | | --- | --- | --- | --- | | 601212.SH | | | | | 云南铜业 | 26.79 | 10.02% | 0.00% | | 000878.SZ | | | | | 中国铝业 | 14.60 | 10.02% | 0.00% | | 601600.SH | | | | | 罗平锌电 | 11.42 | 10.02% | 0.00% | | 002114.SZ | | | | | 中色股份 | 9.00 | 10.02% | 0.00% | | 00 ...

来源：环球网 1月27日，以"AI重塑医药生产力"为主题的2026医药钉峰会在沪召开。西湖大学讲席教授许田、云南白 药集团数字战略科学家李少春、信达生物生产运营副总监钱骏、昭衍新药市场部经理温慧霞、乐普生物 IT高级总监毛磊、圣和医药董事长王勇、海枫生物董事长上药集团原总裁左敏、深势科技CEO孙伟杰、 恒瑞医药董事兼执行副总裁张连山、仙乐健康数字化部门韩冰、钉钉商业总裁杨猛、钉钉行业总经理李 伟、钉钉大健康行业负责人韦亚伟等学界及业界代表齐聚，深入探讨人工智能技术如何驱动赋能医药行 业。 钉钉商业总裁杨猛在开幕致辞中表示，目前超六成医药企业和超半数公立医院都在用钉钉。钉钉愿成为 医药企业的"AI操作系统"，和⼤家⼀起打造⼀张实时运转的全球智能协同⽹，把不确定的时代，做成⼀ 条确定的增⻓曲线。 此外，AI正成为药企全球化协同的基石。针对出海面临的时区、语言与合规挑战，AI能够实现跨时区 会议的智能安排、实时同声传译及系统界面的一键语言切换，助力企业构建无缝衔接的全球一体化运营 网络。 "AI不是替代人，而是让人从重复劳动中解放出来，成为'指挥官'。"钉钉大健康行业负责人韦亚伟在演 讲中指出，AI正从信息、知识、 ...

Market Overview - The Shanghai Composite Index rose by 0.27%, while the Shenzhen Component Index increased by 0.09%. However, the ChiNext Index fell by 0.57% after opening high and dropping over 1% during the day [1] - Over 3,600 stocks in the market experienced declines [2] Sector Performance - Resource stocks led the market, with significant gains in precious metals, oil and gas, and electrolytic aluminum sectors. Notable performances included China Gold with four consecutive trading days of gains, Hunan Gold with three consecutive gains, and China Aluminum hitting a 16-year high [2] - The dyeing and finishing chemicals sector saw collective gains, with Zhejiang Longsheng, Runtou Co., and Yabong Co. reaching their daily price limits [3] - The storage chip sector was active, with Zhongwei Semiconductor and Qipai Technology both hitting their daily price limits [4] - Conversely, the pharmaceutical and medical sectors faced significant declines, with Baipusais and Bibete dropping over 10%, and Heng Rui Pharmaceutical experiencing 11 consecutive days of decline [5] Trading Volume - The total trading volume in the Shanghai and Shenzhen markets reached 2.97 trillion yuan, an increase of 704 billion yuan compared to the previous trading day [6] Individual Stock Highlights - Zijin Mining had a trading volume exceeding 27.2 billion yuan, while Zhongji Xuchuang reached over 20.8 billion yuan in trading volume [7] - Notable individual stock performances included: - Zijin Mining: +4.16%, latest price 42.30 yuan, trading volume 27.285 billion yuan [8] - Zhongji Xuchuang: +2.01%, latest price 628.00 yuan, trading volume 20.819 billion yuan [8] - BlueFocus: -8.29%, latest price 20.36 yuan, trading volume 18.446 billion yuan [8] - Ningde Times: +0.17%, latest price 339.99 yuan, trading volume 15.638 billion yuan [8] - Sunshine Power: -3.34%, latest price 152.90 yuan, trading volume 14.757 billion yuan [8]

Core Viewpoint - The stock market experienced fluctuations with the Shanghai Composite Index and Shenzhen Component Index rising initially but then retreating, while the ChiNext Index opened high but fell, indicating mixed investor sentiment in the market [1] Market Performance - The total trading volume in the Shanghai and Shenzhen markets reached 2.97 trillion yuan, an increase of 70.4 billion yuan compared to the previous trading day [1] - Over 3,600 stocks in the market declined, reflecting a broad sell-off [1] Sector Performance - Resource stocks led the market, with significant gains in precious metals, oil and gas, and electrolytic aluminum sectors. Notable performances included: - China Gold achieving four consecutive trading limit increases - Hunan Gold with three consecutive trading limit increases - China Aluminum hitting a 16-year high with a trading limit increase [1] - The disperse dye concept stocks collectively surged, with Zhejiang Longsheng, Runtou Shares, and Yabang Shares all hitting trading limits [1] - The storage chip concept also showed strong activity, with Zhongwei Semiconductor and Qipai Technology both reaching trading limits [1] Declining Sectors - The pharmaceutical and medical sectors faced significant declines, with notable drops including: - Baipusais and Bibete falling over 10% - Heng Rui Medicine experiencing 11 consecutive days of decline [1] - The photovoltaic sector also saw substantial losses, contributing to the overall market downturn [1] Index Closing - At the close, the Shanghai Composite Index rose by 0.27%, the Shenzhen Component Index increased by 0.09%, while the ChiNext Index fell by 0.57% [1]

Group 1 - The core focus of the 2026 JPM Conference is on the strategic importance of IO (Immuno-Oncology) and ADC (Antibody-Drug Conjugates) in the oncology sector, with a significant emphasis on combination therapies [1] - The conference, held from January 12 to 15, 2026, in San Francisco, is recognized as a key event for insights into new drug development trends, capital flows, and business development collaborations in the healthcare industry [1] - Major multinational corporations (MNCs) are prioritizing second-generation IO and ADC, with a notable contribution from domestic innovations, particularly the introduction of sac-TMT by Merck as a focal point in oncology development [2] Group 2 - The exploration of combination therapies involving IO and ADC is accelerating, with multiple clinical trials underway, including 16 Phase III trials for sac-TMT and 4 Phase III trials for PD-(L)1/VEGF dual antibodies by Pfizer [2] - The year 2026 is identified as a pivotal year for the combination of IO and ADC, with expectations for increased demand for ADCs as they gain a core position in current cancer treatments [3] - Key players in the ADC market include companies such as Kangfang Biopharma, Sanofi, Rongchang Biopharma, and others, indicating a competitive landscape for ADC development [3]

Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry in China [6] Core Insights - The focus remains on the combination of IO (Immuno-Oncology) and ADC (Antibody-Drug Conjugates), with significant advancements expected in their joint application [10][11] - The year 2026 is identified as a critical year for the combination of IO and ADC, with expectations for increased demand for ADCs, particularly in the context of various cancer treatments [11][41] Summary by Sections Section 1: Focus on Second-Generation IO and ADC - Merck's sac-TMT is a strategic focus, with 16 ongoing Phase III clinical trials, particularly in gynecological cancers [14][15] - AstraZeneca has 8 ADCs in clinical stages, with significant data readouts expected in 2026 [19][20] - Pfizer is advancing 4 Phase III clinical trials for its PD-1/VEGF dual antibody SSGJ-707, highlighting its strategic importance in oncology [26][27] - Johnson & Johnson aims to become the leading oncology company by 2030, focusing on multiple myeloma and various cancers [30] - Bristol-Myers Squibb (BMS) is advancing its PD-L1/VEGF dual antibody and oral CELMoD therapies, with significant data catalysts expected in 2026 [32][33] - Roche is focusing on breast cancer, with its oral SERD Giredestrant expected to be approved soon [37][38] Section 2: The Year of IO+ADC Combination - The combination of IO and ADC is seen as a key development direction, with various clinical trials underway [41] - The first-generation IO+ADC combinations are competitive, with sac-TMT emerging as a significant player [42] - The second-generation IO combined with chemotherapy is led by AK112, with multiple milestones expected in the coming years [47] - The second-generation IO combined with ADC is still in early exploration, with AstraZeneca leading the way [49] Section 3: Investment Recommendations and Targets - The report identifies several investment targets, including Kangfang Biotech, 3SBio, and others, highlighting their potential in the oncology sector [11][56]

数据显示，截至2025年12月31日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、恒瑞医药、迈瑞医疗、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.75%。 截至2026年1月28日 13:15，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，新和成领涨 1.70%，兴齐眼药上涨1.39%，艾力斯上涨0.67%；英科医疗领跌。医疗创新ETF(516820)最新报价0.36 元。 东海证券指出，商务部等九部门联合印发的关于促进药品零售行业高质量发展的意见，从转型、支付、 供应、整合四大维度构建行业发展框架，推动行业从"单一卖药"向"健康服务"转型。政策明确鼓励兼并 重组与横向并购，叠加医保定点待遇与基层医疗机构平权、医保个人账户家庭共济等举措，将加速单体 药店出清，行业集中度有望加速提升；优化外配处方审核，打通线下药店处方堵点，允许企业自建药学 服务平台，加速处方外流和市场扩容；鼓励零售药店扩大经营范围，开展健康咨询、中医药文化、养老 照护、便民零售等，打造综合健康服务体。建议关注资金实力雄厚、并购整合能力强，合规运营与精细 ...